it needs to demonstrate efficacy in vivo which to date has not been demonstrated.
and it will be used on well patients not those with disease. the bar is higher for that group.
my opinion remains that it will need to have some kind of trial if it is to be marketed as effective at reducing transmission
that takes time and planning
admittedly a vaccine will not be available for the majority for up to a year.
maybe
anyway good luck and I hope you are right and I am wrong
Ann: 2020 Annual General Meeting, page-18
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.005(4.17%) |
Mkt cap ! $51.50M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 11.5¢ | $96.08K | 801.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 283879 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 145922 | 4 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
12.0¢ |
Change
0.005 ( 4.00 %) |
||||
| Open | High | Low | Volume | ||
| 12.0¢ | 12.0¢ | 11.5¢ | 206768 | ||
| Last updated 15.59pm 08/05/2024 ? | |||||
| SPL (ASX) Chart |